Collegium Pharmaceutical Q3 2023 Earnings Report $29.99 +0.33 (+1.11%) As of 04:00 PM Eastern Earnings HistoryForecast Collegium Pharmaceutical EPS ResultsActual EPS$1.21Consensus EPS $1.11Beat/MissBeat by +$0.10One Year Ago EPSN/ACollegium Pharmaceutical Revenue ResultsActual Revenue$136.71 millionExpected Revenue$139.55 millionBeat/MissMissed by -$2.84 millionYoY Revenue GrowthN/ACollegium Pharmaceutical Announcement DetailsQuarterQ3 2023Date11/7/2023TimeN/AConference Call ResourcesSlide DeckPress ReleaseCOLL Earnings HistoryConference Call AudioYour browser does not support the audio element. Listen Now.Slide DeckFull Screen Slide DeckPowered by Remove Ads Collegium Pharmaceutical Earnings HeadlinesCollegium Announces Poster Presentations at the 2025 National Association of Pediatric Nurse Practitioners National Conference on Pediatric Health CareMarch 10 at 7:05 PM | globenewswire.comCollegium Pharmaceutical's Shareholders Might Be In For A Pain-Free 2025March 9 at 5:00 AM | seekingalpha.comA deadly mistake in my prediction…I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again. March 11, 2025 | Porter & Company (Ad)Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Receives $43.60 Consensus Target Price from AnalystsMarch 9 at 4:13 AM | americanbankingnews.comPiper Sandler Reaffirms Their Hold Rating on Collegium Pharmaceutical (COLL)March 7, 2025 | markets.businessinsider.comCollegium Pharmaceutical's (NASDAQ:COLL) Solid Earnings Are Supported By Other Strong FactorsMarch 6, 2025 | finance.yahoo.comSee More Collegium Pharmaceutical Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Collegium Pharmaceutical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Collegium Pharmaceutical and other key companies, straight to your email. Email Address About Collegium PharmaceuticalCollegium Pharmaceutical (NASDAQ:COLL), a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.View Collegium Pharmaceutical ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles These 3 Q1 Earnings Winners Will Go HigherAnalysts Lift Archer Aviation Stock Despite Earnings Miss DigitalOcean Rides Cloud Wave and AI Hype to Strong EarningsPrice Targets on NVIDIA Rise in Front of EarningsThe Trade Desk Crashes on Earnings, But Growth Catalysts PersistHims & Hers Earnings Could Be a Game Changer—What to Do NowAnalysts See Buying Opportunity in NVIDIA Before Earnings Upcoming Earnings Adobe (3/12/2025)PDD (3/19/2025)Micron Technology (3/20/2025)Accenture (3/20/2025)FedEx (3/20/2025)NIKE (3/20/2025)Cintas (3/26/2025)Paychex (4/1/2025)Bank of New York Mellon (4/11/2025)BlackRock (4/11/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
